NeOnc Technologies’ Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks — Today at 11:00 a.m. ET
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 23 2025
0mins
Source: Globenewswire
NeOnc Technologies Update: NeOnc Technologies Holdings, Inc. is set to feature its Executive Chairman Amir Heshmatpour in a live interview discussing the company's recent Sub-License Agreement with NuroCure and its $50 million partnership with Quazar Investment, aimed at expanding its cancer treatment initiatives in the UAE and MENA regions.
Clinical Advancements: The company is advancing its NEO™ drug development platform, with therapeutics NEO100™ and NEO212™ currently in Phase II clinical trials under FDA Fast-Track status, while also being included in the Russell Microcap Index to enhance market liquidity and attract institutional capital.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
